Breast Cancers Today Videos
Advertisement
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Dr. Sadie Dobrozsi spoke on the importance of genetic testing in breast cancer to better understand the disease.
Dr. Leah Pyter details a study which found that chemotherapy induces microbiome disruption and inflammation in BC patients.
Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.
Carlos Doti, MD, of AstraZeneca, discusses the impact of LYNPARZA over the last decade.
Dr. Lopetegui-Lia reacts to Dr. Gatti-Mays' breast cancer panel discussion from Advancements in Oncology.
Dr. Margaret Gatti-Mays explains what makes The Oncology Brothers' content so important for community oncologists.
Dr. Margaret Gatti-Mays explains how to address the most pressing questions in triple-negative breast cancer treatments.
Dr. Gatti-Mays discusses how treatment for triple-negative breast cancer has evolved in recent years.
Dr. Margaret Gatti-Mays delves into the topic of HER2 tumor expression in breast cancer.
A study examined the impact of relationship satisfaction and agreement between breast cancer survivors and their partners.
Dr. Gatti-Mays talks about the importance of tailoring treatments to individual patients with breast cancer.
Barbara Smith, MD, PhD, discusses the Lumicell Direct Visualization System and how it can enhance breast cancer detection.
Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer.
Dr. Samilia Obeng-Gyasi discusses how social factors can impact outcomes in breast cancer patients.
The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer.
The Oncology Brothers talk with Paolo Tarantino, MD, about the TROPiCS-02 study presented at SABCS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.